Related Experiment Video
Updated: May 20, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
Published on: August 16, 2021
[Cycloferon in the complex therapy of patients with widespread forms of pulmonary tuberculosis]
Abstract:
Research performed at the Grodno Regional Clinical Center "Phthisiology" was aimed at studying the dynamics of IFN-gamma and IL-4 in serum of patients with widespread forms of pulmonary tuberculosis, treated by polychemotherapy with the use of cycloferon. Results of the clinical and laboratory evaluation of the effectiveness of the basic course of treatment are presented. A total of 238 patients, including 32 patients with limited forms of the pulmonary tuberculosis and 206 patients had widespread forms of pulmonary tuberculosis, were randomized into the basic group (BG) and comparison group (CG), where 95 CG patients received only polychemotherapy and 111 BG patients received polychemotherapy with the use of cycloferon. Data on the initial levels of cytokines (IFN-gamma and IL-4) in healthy persons and patients with various spread ofa tubercular inflammation in lungs are presented and compared. It is established that, in patients with widespread forms, initially low level of IFN-gamma and high concentration IL-4 (in comparison with the limited forms) shows a severe disbalance between Th1- and Th2-mediated immune response. The administration of cycloferon in the complex therapy of patients with widespread forms leads to an increase in the IFN-gamma concentration at initially low levels (below median level of this cytokine in healthy humans). Activation of the Th1-mediated immune response upon using cycloferon leads to an early elimination of clinical manifestations of the intoxication syndrome, positive roentgenological dynamics, conversion of sputum smear, and successful outcomes of treatment.
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Antifungal Agents
